23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Company profile
Ticker
ME
Exchange
Website
CEO
Ms. Anne Wojcicki
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
resTORbio, Inc.
SEC CIK
Corporate docs
Subsidiaries
23andMe Holding Co. • 23andMe, Inc. • 23andMe Pharmacy Holdings, Inc. • Lemonaid Health Inc. • Lemonaid Pharmacy Holdings, Inc. • LPharm RX LLC • LPharm INS LLC • LPharm CS LLC • LPRXOne LLC • LPRXTwo LLC ...
ME stock data
Latest filings (excl ownership)
8-K
23andMe Announces 1-for-20 Reverse Stock Split
16 Oct 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Sep 24
8-K
Departure of Directors or Certain Officers
18 Sep 24
8-K
Submission of Matters to a Vote of Security Holders
27 Aug 24
10-Q
2025 Q1
Quarterly report
8 Aug 24
8-K
23andMe Reports First Quarter Fiscal 2025 Financial Results
8 Aug 24
8-K
Regulation FD Disclosure
2 Aug 24
8-K
23andMe announces CEO’s take-private proposal
1 Aug 24
ARS
2024 FY
Annual report to shareholders
16 Jul 24
DEFA14A
Additional proxy soliciting materials
16 Jul 24
Transcripts
ME
Earnings call transcript
2025 Q1
8 Aug 24
ME
Earnings call transcript
2024 Q2
8 Nov 23
ME
Earnings call transcript
2024 Q1
8 Aug 23
ME
Earnings call transcript
2024 Q1
8 Aug 23
ME
Earnings call transcript
2023 Q4
25 May 23
ME
Earnings call transcript
2023 Q3
8 Feb 23
ME
Earnings call transcript
2023 Q2
8 Nov 22
ME
Earnings call transcript
2023 Q1
9 Aug 22
ME
Earnings call transcript
2022 Q4
27 May 22
ME
Earnings call transcript
2022 Q3
11 Feb 22
Latest ownership filings
SC 13G/A
SC US (TTGP), LTD.
21 Oct 24
SC 13D/A
ABeeC 2.0, LLC
30 Sep 24
SC 13D/A
ABeeC 2.0, LLC
18 Sep 24
SC 13D/A
ABeeC 2.0, LLC
11 Sep 24
4
RICHARD H SCHELLER
28 Aug 24
4
RICE VALERIE MD MONTGOMERY
28 Aug 24
4
Neal Mohan
28 Aug 24
4
Patrick S Chung
28 Aug 24
4
ROELOF BOTHA
28 Aug 24
4
Peter J. Taylor
28 Aug 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 24 | Mar 23 | Mar 22 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 180.44 mm | 180.44 mm | 180.44 mm | 180.44 mm | 180.44 mm | 180.44 mm |
Cash burn (monthly) | 14.81 mm | 11.86 mm | 23.99 mm | 53.68 mm | 14.42 mm | 11.52 mm |
Cash used (since last report) | 55.60 mm | 44.52 mm | 90.06 mm | 201.57 mm | 54.16 mm | 43.26 mm |
Cash remaining | 124.85 mm | 135.92 mm | 90.38 mm | -21.13 mm | 126.28 mm | 137.19 mm |
Runway (months of cash) | 8.4 | 11.5 | 3.8 | -0.4 | 8.8 | 11.9 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 148 |
Opened positions | 39 |
Closed positions | 39 |
Increased positions | 27 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 39.15 bn |
Total shares | 258.22 mm |
Total puts | 299.30 k |
Total calls | 270.10 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
ABeeC 2.0 | 98.63 mm | $0.00 |
GSK GSK | 39.66 mm | $116.21 mm |
NewView Capital Partners I | 19.46 mm | $7.59 bn |
NewView Capital Fund I | 19.46 mm | $0.00 |
Vanguard | 15.42 mm | $6.03 bn |
Euclidean Capital | 10.24 mm | $4.01 bn |
Sapphire Ventures, L.L.C. | 5.29 mm | $2.07 bn |
Millennium Management | 4.94 mm | $1.93 bn |
BLK BlackRock | 4.66 mm | $1.82 bn |
Renaissance Technologies | 4.23 mm | $1.65 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Aug 24 | Sandra R MD Hernandez | Class A Common Stock | Grant | Acquire A | No | No | 0.3341 | 149,655 | 50.00 k | 1,203,204 |
26 Aug 24 | Sandra R MD Hernandez | Class A Common Stock | Grant | Acquire A | No | No | 0 | 658,485 | 0.00 | 1,053,549 |
26 Aug 24 | Peter J. Taylor | Class A Common Stock | Grant | Acquire A | No | No | 0 | 658,485 | 0.00 | 981,217 |
26 Aug 24 | Roelof Botha | Class A Common Stock | Grant | Acquire A | Yes | No | 0.3341 | 179,586 | 60.00 k | 483,526 |
26 Aug 24 | Roelof Botha | Class A Common Stock | Grant | Acquire A | No | No | 0 | 658,485 | 0.00 | 658,485 |
26 Aug 24 | Neal Mohan | Class A Common Stock | Grant | Acquire A | No | No | 0 | 658,485 | 0.00 | 904,291 |
26 Aug 24 | Patrick S Chung | Class A Common Stock | Grant | Acquire A | No | No | 0.3341 | 202,035 | 67.50 k | 1,161,941 |
26 Aug 24 | Patrick S Chung | Class A Common Stock | Grant | Acquire A | No | No | 0 | 658,485 | 0.00 | 959,906 |
News
Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants
2 Oct 24
12 Health Care Stocks Moving In Friday's After-Market Session
27 Sep 24
Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time
18 Sep 24
General Mills, Steelcase And 3 Stocks To Watch Heading Into Wednesday
18 Sep 24
Reported Sunday, 23andMe Announced Nonclinical Data Supporting The Anti-tumor Activity Of 23Me-01473 Antibody Targeting NKG2D Ligand ULBP6, At The ESMO Congress
16 Sep 24
Press releases
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
17 Oct 24
23andMe Announces Completion of 1-for-20 Reverse Stock Split
16 Oct 24
23andMe Announces 1-for-20 Reverse Stock Split
11 Oct 24
ME INVESTOR NOTICE: Current 23andMe Holding Co. Shareholders are Notified to Contact BFA Law about Investigation into the Board of Directors (Nasdaq:ME)
1 Oct 24
ME INVESTOR UPDATE: Shareholders of 23andMe Holding Co. are Alerted of Pending Investigation into the Company; Contact BFA Law if You Own Substantial Shares (Nasdaq:ME)
29 Sep 24